

# 北京大学基础医学院 院长论坛

报告题目: Wnt signaling in castration resistant prostate cancer: molecular targets for novel therapy

报告人: Xiaolin Zi, Ph.D. & M.D.

Professor and Director of Urological Research

Department of Urology

University of California, Irvin

报告题目: Targeting Mucins for Pancreatic Cancer Prevention and Treatment

报告人: Chinthalapally V. Rao, Ph.D.

George Lynn Cross Professor

Department of Medicine

Hematology/Oncology Section

University of Oklahoma Health Sciences Center

时 间: 2018 年 9 月 12 日 (星期三) 下午 3:00

地 点: 生理楼二层中厅

主 持 人: 李学军 教授

报告人简介:

The two major areas of Dr. Zi's research in prostate cancer are naturally-occurring bioactive compounds and Wnt signaling with an emphasis on castration-resistant prostate cancer. His publications in Cancer Research, PNAS, et al. that have identified silibinin as a strong antiproliferative and differentiate agent for prostate cancer cells have 1000 resulted in a Phase II clinical trial of silibinin in prostate cancer patients. His NIH funded research discovered that lycopene supplementation can enhance anti-tumor efficacy of docetaxel in a prostate cancer mouse xenograft model. In collaboration with Dr. Michael B. Lilly, Professor, Medical oncologist, and Associate Director for Translational

Research at MUSC's Hollings Cancer Center, the study on lycopene and docetaxel combination in treatment of castration-resistant prostate cancer is also now in Phase I clinical trial. Dr. Zi has mentored 5 graduate students, 13 post-doctoral fellows, and 5 clinical fellows through structured research. He is a program faculty in a NIH T32 grant for Gynecologic Oncology Fellowship at UCI and a faculty member at the NIH funded UCI Cancer Research Institute.

Dr. Rao is an established leader in the field of gastrointestinal cancer chemopreventive drug development and nutritional carcinogenesis. His molecular targeted approaches in developing cancer chemopreventive drugs for colorectal and other epithelial cancer prevention/ treatment are nationally and internationally recognized. Also, Dr. Rao's group is the first to show that combinational molecular targeting provides better synergistic efficacy without unwanted side effects. Dr. Rao led a team of investigators in developing and optimizing animal models for understanding the pathobiology of tumor progression. In the area of dietary factors/ nutritional, immunochemoprevention, Dr. Rao established the role of curcumin, farnesol, diosgenin,  $\beta$ -escin, and frondanol to cite few, as potential chemopreventive agents in colon and pancreatic cancers. Dr. Rao has successfully obtained NIH/NCI peer-reviewed funding for over 28 years and his research identified number of molecular/cellular targets for major epithelial cancers drug development. He has published over 230 articles with over 16,850 citations in lead journals with H-index: 65.

### **Representative Publications:**

1. Zi X, Lusch A, Blair CA, Okhunov Z, Yokoyama NN, Liu S, Baker M, Huynh V, Landm J. Effect of perineoplasm perinephric adipose tissues on migration of clear cell renal c carcinoma cells: a potential role of WNT signaling. *Oncotarget*. 2016; 7 (33), 53277
2. Li Y, Pham V, Bui M, Song L, Wu C, Walia A, Uchio E, Liu-Smith L, Zi X. *Rhodiola rosea* L.: an Herb with Anti-Stress, Anti-Aging, and Immunostimulating Properties for Cancer Chemoprevention. *Current Pharmacology Reports*. 2017 (in press).
3. Wang W, Qin JJ, Li X, Tao G, Wang Q, Wu X, Zhou J, Zi X, Zhang R. Prevention of prostate cancer by natural product MDM2 inhibitor GS25: In vitro and in vivo activities and molecular mechanisms. *Carcinogenesis*. 2018 doi: 10.1093/carcin/bgy063. [Epub ahead of print].
4. Rao CV, Janakiram NB, Mohammed A. Molecular Pathways: Mucins and Drug Delivery in Cancer. *Clin Cancer Res*. 2017 Mar 15;23(6):1373-1378. doi: 10.1158/1078-0432.CCR-16-0862. Epub 2016 Dec 30. PMID: 28039261
5. Rao C, Mohammed A, Asch A, Janakiram N. Immunoprevention of Pancreatic Cancer. *Curr Med Chem*. 2017 Feb 23. doi: 10.2174/0929867324666170223153509. PMID: 28240168.
6. Rao CV, Pal S, Mohammed A, Farooqui M, Doescher MP, Asch AS, Yamada HY. Biological effects and epidemiological consequences of arsenic exposure, and reagents that can ameliorate arsenic damage in vivo. *Oncotarget*. 2017 May 10;8(34):57605-57621. doi: 10.18632/oncotarget.17745. eCollection 2017. PMID: 28915699

欢迎师生参加!